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Abstract
Aims: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, associated with alterations of
bowel function, abdominal pain and other symptoms related to the GI tract. Recently the endogenous cannabinoid
system (ECS) was shown to be involved in the physiological and pathophysiological control of the GI function. The
aim of this pilot study was to investigate whether IBS defining symptoms correlate with changes in endocannabinoids
or cannabinoid like fatty acid levels in IBS patients.
Methods: AEA, 2-AG, OEA and PEA plasma levels were determined in diarrhoea-predominant (IBS-D) and
constipation-predominant (IBS-C) patients and were compared to healthy subjects, following the establishment of
correlations between biolipid contents and disease symptoms. FAAH mRNA levels were evaluated in colonic
biopsies from IBS-D and IBS-C patients and matched controls.
Results: Patients with IBS-D had higher levels of 2AG and lower levels of OEA and PEA. In contrast, patients with
IBS-C had higher levels of OEA. Multivariate analysis found that lower PEA levels are associated with cramping
abdominal pain. FAAH mRNA levels were lower in patients with IBS-C.
Conclusion: IBS subtypes and their symptoms show distinct alterations of endocannabinoid and endocannabinoid-
like fatty acid levels. These changes may partially result from reduced FAAH expression. The here reported changes
support the notion that the ECS is involved in the pathophysiology of IBS and the development of IBS symptoms.
Citation: Fichna J, Wood JT, Papanastasiou M, Vadivel SK, Oprocha P, et al. (2013) Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels
Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study. PLoS ONE 8(12): e85073. doi:10.1371/journal.pone.0085073
Editor: Michal Zmijewski, Medical University of Gdańsk, Poland
Received October 26, 2013; Accepted November 22, 2013; Published December 27, 2013
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by
anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by the University of Calgary Research Grant Committee (to MS), the Iuventus Plus program of the Polish Ministry of
Science and Higher Education (0119/IP1/2011/71 and 0107/IP1/2013/72 to JF), and the Deutsche Forschungsgemeinschaft (STO 645/6-1 to MS). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: Martin.Storr@med.uni-muenchen.de
Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal
(GI) disorder, associated with alterations of bowel function and
other symptoms related to the GI tract, such as abdominal pain
or cramping (localized, intermittent pain), bloating or feeling of
incomplete evacuation. The prevalence of IBS is estimated at
up to 20% in the Western countries [1,2] and accounts for more
than 50% of referrals to GI specialists [3–5]. IBS has a major
impact on patient’s quality of life, and accounts for a heavy
burden for, patients, health care providers and economies. Due
to the lack of efficient treatments, there is an unmet need to
develop novel anti-IBS strategies.
The design of novel therapeutics to be used in IBS is
impaired by our incomplete understanding of the
pathophysiology of IBS and therefore the poor control of the
changes in endogenous systems during IBS development.
Therefore the systems that are well-known for their
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involvement in pain signalling and GI motility are currently
regarded as being a main potential target for future anti-IBS
drugs. The endogenous cannabinoid system (ECS), which
consists of three principal pillars, i.e. “classical” cannabinoid
(CB1, CB2) and “non-classical” (TRPV1, GPR55) receptors,
endogenous ligands (anandamide, AEA; 2-
arachidonyloglycerol, 2-AG) and the cluster of enzymes,
responsible for CB synthesis and degradation [6] has recently
attracted much attention as a crucial site in IBS
pathophysiology. The localization of CB1 and CB2 receptors
and their endogenous ligands in the GI tract and in sensory
endings on primary sensory afferents [7–11], as well as
participation of the ECS in pain signalling, modulation of
sensory afferent information and GI peristalsis (for review, see:
[6,12]) have been well established. However, much attention
has currently been given to the fatty acid amide hydrolase
(FAAH) and its metabolites. FAAH is an intracellular enzyme,
primarily located in the liver and the brain, as well as in
peripheral organs, like the GI tract (for review, see: [13]). It is
commonly accepted that AEA is the main substrate for FAAH,
but a growing body of evidence points that 2-AG, although not
exclusively, is also deactivated by this hydrolase [14]. FAAH is
also involved in the degradation of several other biolipids,
including palmitoylethanolamide (PEA) and oleoylethanolamide
(OEA), which may bind to both, “classical” and “non-classical”
CB receptors. Therefore it has been suggested that the
modulators of the FAAH activity, as potential anti-IBS
therapeutics, may provide finer tuning of the ECS function than
the CB receptor ligands, also in terms of peripheral vs. central
site-dependent site effects.
To further clarify whether the ECS is involved in IBS
pathophysiology and whether changes in ECB or cannabinoid-
like fatty acid amide levels contribute to clinical symptoms we
established ECB and cannabinoid-like fatty acid amide levels in
female patients with IBS. The levels where then correlated with
IBS subtypes, namely IBS-D and IBS-C and, additionally, with
the self-reported symptom scores and compared to age-
matched female control group. Finally, FAAH mRNA levels
were evaluated in colonic biopsies from female IBS-D and IBS-
C patients and matched controls to investigate whether
changes in FAAH expression at the transcription level
contribute to the observed changes in metabolite
concentrations. The correlations observed may provide a new
understanding of the mechanisms underlying IBS and




Human studies were approved by the Ethics Committee of
the University of Calgary, Canada and Medical University of
Lodz, Poland. All participating subjects gave written, informed
consent prior to genetic analysis.
Patients
Endocannabinoid and cannabinoid-like fatty acid amide
levels were quantified in plasma from female IBS-D and IBS-C
patients and healthy controls at the GI-clinic of the University of
Calgary, Canada. In total 21 blood samples were analyzed.
The study population comprised 7 patients with IBS-D (age
26-58), 7 patients with IBS-C (age 21-62), and 7 healthy
subjects (age 29-56).
To quantify the relative expression of human FAAH, forceps
biopsy samples were analyzed. In total 16 samples prepared
from human colon biopsies were used for the study. The study
population comprised 3 patients with IBS-D (age 43-71), 3
patients with IBS-C (age 25-62) and 10 healthy, unrelated
controls (age 33-82) recruited from January 2011 to December
2012 at the Medical University of Lodz, Poland.
The diagnosis of IBS-D and IBS-C was assessed according
to established clinical criteria using endoscopic, radiologic, and
histopathologic examinations.
Endocannabinoid and and cannabinoid-like fatty acid
amide extraction from plasma
After collection, human plasma samples from each patient
were kept at room temperature for 1,30, 60 and 120 minutes
and were then immediately stored at -80°C until they were
processed and analyzed. The extraction procedure for the
standards, made in 20 mg/mL fatty acid free BSA, quality
control samples, made in BSA, unextracted quality control
samples, made in ethanol, and plasma samples was a modified
version of the Folch extraction [15–17]. Proteins were
precipitated in the standards, quality controls made in BSA and
plasma samples using ice cold acetone:PBS, pH 7.4 (3:1) and
internal standard, followed by centrifugation at 13,000 g for 5
minutes at 4°C. The resulting supernatant from all samples was
dried under nitrogen until the acetone was removed. To the
remaining supernatant, 100 µL PBS, one volume of methanol
and two volumes of chloroform was added for liquid-liquid
phase extraction of the lipids. The two phases were separated
by centrifugation and the bottom organic layer was evaporated
to dryness under nitrogen. Samples were reconstituted in 50 µL
ethanol and were vortexed, sonicated briefly and centrifuged
prior to analysis.
Nano LC-MS analysis for endocannabinoids
Samples were loaded on a C4 LC trap (5 µm, 300 A, Bruker-
Michrom, Auburn, CA, USA) with water/acetonitrile/formic acid
(80/20/0.1) at a flow rate of 10 µL/min for 3 min.
Chromatographic separation was achieved using a Michro-
Tech Scientific C18 column (50 mm, 75 µm ID, 3 µm particle,
120 A pore size) on an ABI 4000 Q-Trap mass spectrometer
with a Tempo nano-LC on the front end (Applied Biosystems
Inc., Framingham, MA). The mobile phase consisted of water/
acetonitrile (95/5; A) and acetonitrile/water (95/5; B), with 0.1%
formic acid in both, in the following two step gradient: initial
conditions of 80% A decreased linearly to 20% A over 1 minute
and to 100% B in 9 min. The system was held at these
conditions for 5 minutes before returning to initial conditions
(flow rate = 700 nl/min); the autosampler was kept at 4°C to
prevent analyte degradation. The sample injection volume was
1µL and the reagent used to fill the loop (10 µL) was water/
acetonitrile (95/5) with 0.1% formic acid. Eluted peaks were
ionized using a nanoESI source on a 4000Qtrap (Applied
Endocannabinoids in IBS
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Biosystems) in positive mode and detected by multiple reaction
monitoring (MRM). Deuterated internal standards were used for
each standard curve and the levels of each endocannabinoid
or cannabinoid-like fatty acid amide per mL plasma were
determined.
Standard curves were linear with a regression value of
>0.993. Extraction efficiencies were greater than 85% for each
compound and deuterated standard.
Real-time reverse transcriptase (RT) PCR and
quantification of FAAH expression in human biopsies
The biopsy specimens were immediately frozen after
isolation and kept at -70°C until processing. The RNA was
isolated using the PureLink RNA Mini kit (Life Technologies,
Carlsbad, CA, USA) according to manufacturer’s protocol. The
purity and quantity of isolated RNA was measured using
dedicated spectrophotometer (BioPhotometer; Eppendorf,
Germany). Total RNA (1 μg) was used for cDNA synthesis
using a first strand cDNA synthesis kit (Fermentas, Canada).
Quantitative analysis was performed using fluorescently
labeled TaqMan probes Hs00155015_m1 and
Hs01003267_m1 for human FAAH and hypoxanthine-guanine
phosphoribosyltransferase (HPRT, endogenous control),
respectively (Life Technologies, Carlsbad, CA, USA) on
Mastercycler S realplex 4 apparatus (Eppendorf, Germany). All
experiments were performed in triplicates.
The Ct values for studied genes were normalized to Ct
values obtained for a housekeeping gene HPRT. Relative
amount of mRNA copies was calculated using 2^-ΔCt method.
For presentation, relative copy number values were
recalculated to number of copies of each studied gene per
1000 copies of HPRT. The mean Ct values for the
housekeeping gene (HPRT) in samples from all patient groups
did not alter regardless of the studied group.
Statistical analysis
Statistical analysis was performed in R software environment
for statistical computing.
Level of significance was set in all tests to P ≤ 0.05.
Statistical significance in the differences in levels (measured
after 0, 30, 60 and 120 min) of AEA, 2-AG, OEA and PEA for
different symptoms was tested using multivariate analysis of
variance (MANOVA; 4 different tests were used: Pillai, Wilks,
Hotelling-Lawley and Roy test). Each symptom was treated
separately and compared with control group. In the case of
symptoms, which showed difference in levels, an analysis of
variance was applied (one-way ANOVA) to each measurement
time (0, 30, 60, and 120 min). The LSD test was used in post
hoc analysis (with Holm's p value adjustment). To establish
correlations between disease type and specific symptoms, the
χ2 test with Bonferroni correction was used.
ANOVA followed by Bonferroni post-hoc testing was used to
assess the differences among relative FAAH mRNA levels. P
values < 0.05 were considered statistically significant.
Figures were prepared using Prism 5.0 (GraphPad Software
Inc., La Jolla, CA, USA).
Results
Endocannabinoid and cannabinoid-like fatty acid amide
plasma levels change with stool pattern in IBS
Endocannabinoid (AEA, 2-AG) and cannabinoid-like fatty
acid amide (OEA, PEA) levels were detected in all plasma
samples from IBS-D and IBS-C patients and healthy controls.
In all patients AEA, OEA and PEA levels increased, while 2-AG
level did not change over the time of the study, suggesting the
release from peripheral blood cells, an observation which is
congruent with earlier reported results [17]. In IBS-D patients,
2-AG levels were higher, whereas OEA and PEA levels were
lower than in healthy controls (Figure 1). In contrast, OEA
plasma levels were higher in IBS-C patients vs. healthy
subjects.
MANOVA analysis showed no significant correlation between
endocannabinoid and cannabinoid-like fatty acid amide plasma
levels and IBS type.
IBS type is significantly correlated with specific
symptoms
As expected, the abdominal pain was significantly more
common in IBS-D (p= 0.0009995002 vs. controls) and IBS-C
patients (p=0.001999 vs. controls) compared to healthy
subjects. Also, there was a significant correlation between
dysmotility symptoms and the IBS type (p=0.001999 for IBS-D
and p=0.00149925 for IBS-C vs. controls).
Of note, IBS-D, but not IBS-C patients suffered from
abdominal cramping (p=0.0009995002) in comparison with
healthy controls.
PEA plasma levels are correlated with abdominal
cramping frequency in IBS patients
As shown in Figure 2, PEA levels were considerably lower in
IBS-D and IBS-C patients with daily cramping, but equal or
increased in patients suffering from >1/week or less frequent
cramping, compared to healthy subjects. Low levels of PEA
were detected in IBS-C patients with no symptoms of cramping
(Figure 2).
Decreased FAAH expression in IBS-C patients vs.
healthy controls
There was no difference in the FAAH expression at mRNA
level between female IBS-D patients and healthy controls
(Figure 3). However, a significant decrease in FAAH mRNA
levels was detected in colonic biopsies from female IBS-C
patients compared to healthy controls.
Discussion
In this preliminary study on a small cohort of IBS patients we
have shown that the biolipid turnover may play a crucial role in
the pathophysiology of IBS and the levels of FAAH metabolites
correlate with the motility pattern and disease symptoms. We
have also observed that FAAH mRNA levels are correlated
with the IBS type and a significant decrease in FAAH mRNA
expression was confirmed in patients suffering from IBS-C.
Endocannabinoids in IBS
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Finally, we have demonstrated that the biolipid turnover in IBS,
although greatly dependent on FAAH activity, is also regulated
by other enzymatic pathways, which need further elucidation.
Cannabinoids have been used for centuries for recreational
purposes, but only relatively recently their potential clinical
action attracted much attention. Although the localization and
function of the components of ECS are not fully understood
and are still under investigation in several systems [18,19], it
has become evident that they play a crucial role in functional GI
disorders, such as IBS, and targeting the ECS may become
one of major sites of action of anti-IBS treatments. Targeting
CB receptors, which are localized on the neural, immune and
other non-neural cells, by endogenous and exogenous
cannabinoids may alter central or enteric GI muscle excitation
[20] and visceral hypersensitivity (for review, see: [6]).
However, in extensive clinical studies CB receptor ligands, like
dronabinol and Δ9-tetrahydrocannabinol, failed to produce a
simultaneous relief of both major symptoms of IBS, pain and
Figure 1.  Endocannabinoid (anandamide, AEA; 2-arachidonoyl glycerol, 2-AG) and cannabinoid-like fatty acid amide (N-
oleoyl ethanolamine, OEA; N-palmitoyl ethanolamine, PEA) levels in plasma 0, 30, 60 and 120 min after blood sample
collection from IBS-D and IBS-C patients vs.  healthy controls.
The results are shown as mean ± SEM of n=7 for each group. Each sample was run in triplicate.
doi: 10.1371/journal.pone.0085073.g001
Endocannabinoids in IBS
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Figure 2.  PEA levels in plasma from IBS patients.  PEA levels in plasma 0, 30, 60 and 120 min after blood sample collection
from IBS-D (A) and IBS-C (B) patients vs. abdominal cramping frequency.
The results are shown as mean ± SEM of n=7 for each group. Each sample was run in triplicate.
doi: 10.1371/journal.pone.0085073.g002
Endocannabinoids in IBS
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changes in motility patterns [21]; they were also shown to act in
the central nervous system and thus produced side effects at
higher doses, which may have masked the potential beneficial
action [22]. In contrast, FAAH and MAGL blockers produce
potent antinociceptive effects and regulate GI motility.
However, behavioral side effects typical for CB agonists are
absent only in animals treated with selective FAAH [23,24], but
not selective MAGL or mixed FAAH/MAGL inhibitors [25–27].
Moreover, sustained FAAH blockade does not alter CB1
receptor function and lacks dependence liability [28,29],
suggesting that blocking the enzyme is a promising anti-IBS
strategy. FAAH as a potential target in IBS treatment has also
been proposed by the group of M. Camilleri, who investigated
genetic variation in endocannabinoid metabolism in IBS
patients [21,30,31].
Our study suggests that the motility patterns in IBS patients
may correlate with biolipid serum levels. The endocannabinoid
and cannabinoid-like fatty acid amide homeostasis is finely
tuned in human body by synthesis on demand and rapid
intracellular degradation, in which both degrading enzymes and
transmembrane transporters are involved. Our observations
require thus further extension, since prolonged changes in the
biolipid equilibrium may have both, diagnostic and therapeutic
implications. Furthermore, our data suggests that not only
typical endocannabinoids, but also biolipids binding to “non-
classical” CB receptors may be involved in the IBS
pathophysiology, what could be important for the
understanding of the disease. Earlier studies focused mainly on
AEA and 2-AG in the colon and small intestine and showed
that AEA may be the major endocannabinoid influencing GI
function [32,33]. However, it was later reported that
cannabinoid-like fatty acid amides, such as PEA and OEA, can
also be found in the GI tract and are able to reduce intestinal
motility [34–36]. Although there is conflicting data on the
involvement of the “non-classical” CB receptors in the anti-
motility effect and the modulation of basal visceral sensitivity by
PEA and OEA, which still needs to be elucidated [37–39], it is
apparent that several components of the ECS play important
roles in the development of IBS.
Finally, we have shown that the FAAH mRNA expression is
decreased in patients with IBS-C. This suggests slower
turnover of endocannabinoids and may in part elegantly explain
the slowing of motility, a typical feature of IBS-C. However,
lower FAAH mRNA levels are in contrast with decreased PEA
concentrations found in the IBS-C patient plasma, since this
fatty acid amide is one of the substrates for FAAH and should
be accumulated in the absence of enzyme activity. This
suggests that other degradation enzymes are involved in PEA
metabolism in the course of IBS. On the other hand, since
samples for quantification of FAAH mRNA expression and
endocannabinoid levels originated from two separate groups of
patients, this hypothesis needs further elucidation.
In conclusion, our study shows that two major pillars of the
ECS, the enzyme FAAH and its metabolites, correlate with IBS
subtypes and IBS symptoms, whereas the basal release of the
biolipids is not altered. Here we report that the alterations in
endocannabinoids or cannabinoid-like fatty acid amides are
associated with symptoms arising from altered motility and
nociception and suggest their pathophysiological involvement.
For IBS-C, the increased OEA levels may be due to the
reduced FAAH expression and in consequence contribute to
delayed intestinal transit in these patients. In contrast, the
reduced OEA levels in patients with IBS-D may contribute to
the increased GI transit. Our study furthermore provides
evidence that the biolipid PEA level is lower in patients who
report daily cramping and we suggest that the lack of PEA,
which was shown to induce antinociception in animals, is an
important component underlying the increased abdominal pain
Figure 3.  FAAH mRNA expression in colonic biopsies from patients with IBS-D and IBS-C vs. healthy controls.  The results
are shown as mean ± SEM.
doi: 10.1371/journal.pone.0085073.g003
Endocannabinoids in IBS
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in patients with both IBS subtypes. Finally, our study for the
first time shows that altered FAAH expression and distinct
alterations in ECB or cannabinoid-like fatty acid amide levels
are associated with motility phenomena like diarrhea and
constipation, as well as symptoms of increased nociception
and constitute that the endocannabinoid system is a crucial
player in the pathophysiology of IBS. However, since samples
for quantification of FAAH mRNA expression and
endocannabinoid levels originated from two separate groups of
patients, this hypothesis needs further elucidation.
Author Contributions
Conceived and designed the experiments: JF M. Storr.
Performed the experiments: JF JTW MP SKV M. Sałaga M.
Sobczak A. Mokrowiecka AIC PKZ. Analyzed the data: JF PO
PK. Contributed reagents/materials/analysis tools: JF EMP
WMK A. Makriyannis M. Storr. Wrote the manuscript: JF A.
Makriyannis M. Storr.
References
1. Jones R, Lydeard S (1992) Irritable bowel syndrome in the general
population. BMJ 304: 87-90. doi:10.1136/bmj.304.6819.87. PubMed:
1737146.
2. Talley NJ, Zinsmeister AR, Van DC, Melton LJ III (1991) Epidemiology
of colonic symptoms and the irritable bowel syndrome.
Gastroenterology 101: 927-934. PubMed: 1889716.
3. Jones J, Boorman J, Cann P, Forbes A, Gomborone J et al. (2000)
British Society of Gastroenterology guidelines for the management of
the irritable bowel syndrome. Gut 47 Suppl 2: ii1-i19. doi:10.1136/gut.
47.1.1. PubMed: 11053260.
4. Sandler RS, Drossman DA, Nathan HP, McKee DC (1984) Symptom
complaints and health care seeking behavior in subjects with bowel
dysfunction. Gastroenterology 87: 314-318. PubMed: 6735075.
5. Akbar A, Walters JR, Ghosh S (2009) Review article: visceral
hypersensitivity in irritable bowel syndrome: molecular mechanisms
and therapeutic agents. Aliment Pharmacol Ther 30: 423-435. doi:
10.1111/j.1365-2036.2009.04056.x. PubMed: 19493256.
6. Storr MA, Sharkey KA (2007) The endocannabinoid system and gut-
brain signalling. Curr Opin Pharmacol 7: 575-582. doi:10.1016/j.coph.
2007.08.008. PubMed: 17904903.
7. Kulkarni-Narla A, Brown DR (2000) Localization of CB1-cannabinoid
receptor immunoreactivity in the porcine enteric nervous system. Cell
Tissue Res 302: 73-80. doi:10.1007/s004410000261. PubMed:
11079717.
8. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S (2002)
Localisation of cannabinoid CB(1) receptor immunoreactivity in the
guinea pig and rat myenteric plexus. J Comp Neurol 448: 410-422. doi:
10.1002/cne.10270. PubMed: 12115703.
9. Bridges D, Rice AS, Egertová M, Elphick MR, Winter J et al. (2003)
Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using
in situ hybridisation and immunohistochemistry. Neuroscience 119:
803-812. doi:10.1016/S0306-4522(03)00200-8. PubMed: 12809701.
10. Casu MA, Porcella A, Ruiu S, Saba P, Marchese G et al. (2003)
Differential distribution of functional cannabinoid CB1 receptors in the
mouse gastroenteric tract. Eur J Pharmacol 459: 97-105. doi:10.1016/
S0014-2999(02)02830-3. PubMed: 12505538.
11. MacNaughton WK, Van S, Keenan CM, Cushing K, Mackie K et al.
(2004) Distribution and function of the cannabinoid-1 receptor in the
modulation of ion transport in the guinea pig ileum: relationship to
capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol
286: G863-G871. doi:10.1152/ajpgi.00482.2003. PubMed: 14701723.
12. Croxford JL (2003) Therapeutic potential of cannabinoids in CNS
disease. CNS Drugs 17: 179-202. doi:
10.2165/00023210-200317030-00004. PubMed: 12617697.
13. Ueda N, Yamamoto S (2000) Anandamide amidohydrolase (fatty acid
amide hydrolase). Prostaglandins Other Lipid Mediat 61: 19-28. doi:
10.1016/S0090-6980(00)00052-6. PubMed: 10785539.
14. Di M, V, De PL, Bisogno T (2001) Endocannabinoids Part I: molecular
basis of endocannabinoid formation, action and inactivation and
development of selective inhibitors. Expert Opin Ther Targets 5:
241-265. doi:10.1517/14728222.5.2.241. PubMed: 15992179.
15. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the
isolation and purification of total lipides from animal tissues. J Biol
Chem 226: 497-509. PubMed: 13428781.
16. Williams J, Wood J, Pandarinathan L, Karanian DA, Bahr BA et al.
(2007) Quantitative method for the profiling of the endocannabinoid
metabolome by LC-atmospheric pressure chemical ionization-MS. Anal
Chem 79: 5582-5593. doi:10.1021/ac0624086. PubMed: 17600384.
17. Wood JT, Williams JS, Pandarinathan L, Courville A, Keplinger MR,
Janero et al. (2008) Comprehensive profiling of the human circulating
endocannabinoid metabolome: clinical sampling and sample storage
parameters. Clin Chem Lab Med 46: 1289-1295. PubMed: 18611105.
18. Brocato B, Zoerner AA, Janjetovic Z, Skobowiat C, Gupta S, et al.
(2013) Endocannabinoid crosstalk between placenta and maternal fat
in a baboon model (Papio spp.) of obesity. Placenta 34: 983-989.
S0143-4004(13)00692-9 [pii];Available online at: 10.1016/j.placenta.
2013.08.007 [doi]
19. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, et
al. (2012) Sensing the environment: regulation of local and global
homeostasis by the skin's neuroendocrine system. Adv Anat Embryol
Cell Biol 212: v, vii, 1-v, vii115
20. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K et al. (2007)
Effects of a cannabinoid receptor agonist on colonic motor and sensory
functions in humans: a randomized, placebo-controlled study. Am J
Physiol Gastrointest Liver Physiol 293: G137-G145. doi:10.1152/ajpgi.
00565.2006. PubMed: 17395895.
21. Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA et al. (2011)
Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting
colonic motility in patients with nonconstipated irritable bowel
syndrome. Gastroenterology 141: 1638-1647. doi:10.1053/j.gastro.
2011.07.036. PubMed: 21803011.
22. Fox A, Bevan S (2005) Therapeutic potential of cannabinoid receptor
agonists as analgesic agents. Expert Opin Investig Drugs 14: 695-703.
doi:10.1517/13543784.14.6.695. PubMed: 16004597.
23. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK et al.
(2001) Supersensitivity to anandamide and enhanced endogenous
cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc
Natl Acad Sci U S A 98: 9371-9376. doi:10.1073/pnas.161191698.
PubMed: 11470906.
24. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A et al. (2003)
Modulation of anxiety through blockade of anandamide hydrolysis. Nat
Med 9: 76-81. PubMed: 12461523.
25. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA et al.
(2011) Blockade of endocannabinoid hydrolytic enzymes attenuates
precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp
Ther 339: 173-185. doi:10.1124/jpet.111.181370. PubMed: 21719468.
26. Long JZ, Nomura DK, Cravatt BF (2009) Characterization of
monoacylglycerol lipase inhibition reveals differences in central and
peripheral endocannabinoid metabolism. Chem. Biol 16: 744-753.
27. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L et al. (2009)
Dual blockade of FAAH and MAGL identifies behavioral processes
regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S
A 106: 20270-20275. doi:10.1073/pnas.0909411106. PubMed:
19918051.
28. Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ et al.
(2009) Inhibitors of endocannabinoid-metabolizing enzymes reduce
precipitated withdrawal responses in THC-dependent mice. AAPS J 11:
342-352. doi:10.1208/s12248-009-9110-7. PubMed: 19430909.
29. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B et al. (2010)
Chronic monoacylglycerol lipase blockade causes functional
antagonism of the endocannabinoid system. Nat Neurosci 13:
1113-1119. doi:10.1038/nn.2616. PubMed: 20729846.
30. Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M et al. (2012)
Randomized pharmacodynamic and pharmacogenetic trial of
dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.
Neurogastroenterol Motil 24: 358-e169. doi:10.1111/j.
1365-2982.2011.01874.x. PubMed: 22288893.
31. Camilleri M, Carlson P, McKinzie S, Grudell A, Busciglio I, et al. (2008)
Genetic variation in endocannabinoid metabolism, gastrointestinal
motility, and sensation. Am J Physiol Gastrointest Liver Physiol 294:
G13-G19 00371.2007 [pii];Available online at: 10.1152/ajpgi.
00371.2007 [doi]
32. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L et al. (2001)
Cannabinoid CB1-receptor mediated regulation of gastrointestinal
Endocannabinoids in IBS
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e85073
motility in mice in a model of intestinal inflammation. Br J Pharmacol
134: 563-570. doi:10.1038/sj.bjp.0704293. PubMed: 11588110.
33. Obata T, Sakurai Y, Kase Y, Tanifuji Y, Horiguchi T (2003)
Simultaneous determination of endocannabinoids
(arachidonylethanolamide and 2-arachidonylglycerol) and isoprostane
(8-epiprostaglandin F2alpha) by gas chromatography-mass
spectrometry-selected ion monitoring for medical samples. J
Chromatogr B Analyt Technol Biomed Life Sci 792: 131-140. doi:
10.1016/S1570-0232(03)00311-8. PubMed: 12829006.
34. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F et al. (2001)
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in
mice. Br J Pharmacol 134: 945-950. doi:10.1038/sj.bjp.0704339.
PubMed: 11682441.
35. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K et al.
(2002) Endocannabinoids as physiological regulators of colonic
propulsion in mice. Gastroenterology 123: 227-234. doi:10.1053/gast.
2002.34242. PubMed: 12105851.
36. Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA (2009) The
identification of peroxisome proliferator-activated receptor alpha-
independent effects of oleoylethanolamide on intestinal transit in mice.
Neurogastroenterol Motil 21: 420-429. doi:10.1111/j.
1365-2982.2008.01248.x. PubMed: 19140957.
37. Brusberg M, Arvidsson S, Kang D, Larsson H, Lindström E et al. (2009)
CB1 receptors mediate the analgesic effects of cannabinoids on
colorectal distension-induced visceral pain in rodents. J Neurosci 29:
1554-1564. doi:10.1523/JNEUROSCI.5166-08.2009. PubMed:
19193902.
38. Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ (2002) The
palmitoylethanolamide family: a new class of anti-inflammatory agents?
Curr Med Chem 9: 663-674. doi:10.2174/0929867023370707. PubMed:
11945130.
39. Li K, Fichna J, Schicho R, Saur D, Bashashati M et al. (2013) A role for
O-1602 and G protein-coupled receptor GPR55 in the control of colonic
motility in mice. Neuropharmacology 71: 255-263. doi:10.1016/
j.neuropharm.2013.03.029. PubMed: 23603203.
Endocannabinoids in IBS
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e85073
